Heart Failure

Approximately 24 to 25% of patients with type 2 diabetes and heart failure died within 18 months.

Patients with heart failure who have had 3 or more vaccines had a 55% decreased risk of developing dementia.

Fee-for-Service Medicare beneficiaries with heart failure accounted for 55.3% of readmissions.

This article explores recent evidence describing the potential benefits of vitamin D supplementation in patients with heart failure and reduced ejection fraction.

The American College of Cardiology, American Heart Association, and Heart Failure Society of America recently updated guidelines for pharmacological heart failure treatment, focusing specifically on 2 new agents.

Patients with heart failure who exercise show an 18% decreased risk of all-cause mortality compared with patients who do not exercise.

Approximately 25% of patients develop heart failure within 4 years after the patients’ first heart attack.

The American College of Cardiology, the American Heart Association, and the Heart Failure Society of America have updated heart failure guidelines to recommend the use of 2 medications: sacubitril/valsartan (Entresto) and ivabradine (Corlanor).

This article highlights the latest evidence from both the AHA/ACC and ESC guidelines, which were both published this past weekend.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.

Entresto found to benefit clinically stable heat failure patients as much as the least-stable patients.

Novartis' sacubitril/valsartan (Entresto) is showing promise for heart failure patients with reduced ejection fraction, regardless of background therapy or clinical stability.

Study finds a limit to the benefits of renin-angiotensin system blockers for heart failure.

ENTRESTOâ„¢ (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg, from Novartis Pharmaceuticals Corporation, are a combination of an angiotensin receptor blocker and a novel neprilysin inhibitor, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association class II through IV) and reduced ejection fraction.

Sneha Srivastava, PharmD, BCACP, discusses how pharmacists can work toward improving outcomes for patients recently discharged after heart failure.

Sneha Srivastava, PharmD, BCACP, discusses the new and emerging therapies to treat heart failure.

Sneha Srivastava, PharmD, BCACP, describes the role of the pharmacist at the time of discharge for heart failure patients.

the community pharmacist is in a unique position to provide another level of education to heart failure patients.

Left ventricular assist devices have emerged as a lifesaving treatment option for those with advanced heart failure.

One way to help patients with heart failure is identifying signs of decompensation early.

Pharmacists may want to steer their patients toward a resource for their cardiovascular health: the Life’s Simple 7 test from the American Heart Association.

Atrial fibrillation can be a tricky condition because patients may not know that they have it, as they may not exhibit any symptoms.

Pharmacists and other health care providers use the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults as a guideline for prescribing medications for older adults.

Joel Marrs, PharmD, BCPS-AQ Cardiology, FASHP, discusses how the approval of Entresto changed the heart failure care landscape.